Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ERC 1671

Next Previous
X
Search
Drug Profile

ERC 1671

Alternative Names: ERC-1671; Gliovac™; Sitoiganap

Latest Information Update: 27 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epitopoietic Research Corporation
  • Developer Epitopoietic Research Corporation; University of California at Irvine
  • Class Brain cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Gliosarcoma

Most Recent Events

  • 26 Jul 2022 Epitopoietic Research Corporation plans to submit priority review to US FDA
  • 26 Jul 2022 ERC 1671 receives Fast Track designation for Glioblastoma [Intradermal,Injection] (Combination therapy, Recurrent, Second-line therapy or greater) in USA
  • 26 Jul 2022 ERC 1671 receives Fast Track designation for Gliosarcoma [Intradermal,Injection] (Combination therapy, Recurrent) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top